Company page

Prelude Therapeutics Incorporated

Prelude Therapeutics Incorporated, trading under the ticker PRLD, operates in the American market with a market capitalization of approximately $344 million. The company focuses on developing innovative therapies for cancer treatment. Prelude Therapeutics is committed to advancing its pipeline of drug candidates to address unmet medical needs in oncology.